Global Immunomodulators Market – Industry Trends and Forecast to 2030

Global Immunomodulators Market, By Product (Immunosuppressant, Immunostimulants, Others), Application (Respiratory, Human Immunodeficiency Virus (HIV), Oncology, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.

Immunomodulators Market Analysis and Size

The increase in adoption of early immunomodulator therapy for the treatment of Crohn's disease across the globe acts as one of the major factors driving the growth of immunomodulators market. The rise in incidence of chronic diseases such as asthma, allergic conditions, cancer, and multiple sclerosis, and availability of effective product pipeline of the companies involved in research and development of immunomodulators accelerate the market growth. The presence of high unmet clinical needs with regard to treatment for immune disorders, such as rheumatoid arthritis, and increase in number of ongoing clinical trials for the development of immunotherapeutic agents, such as laquinimod, and ozanimod further influence the market. Additionally, increase in the population, surge in healthcare expenditure, improved healthcare infrastructure, growth of awareness, and expansion of biotechnology and pharmaceutical sectors extend profitable opportunity to the market players in the forecast period of 2023 to 2030.

Data Bridge Market Research analyses that the immunomodulators market which was USD 217.1 million in 2022, and would rocket up to USD 364.7 million by 2030, and is expected to undergo a CAGR of 6.7% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user segment of the immunomodulators market owing to the increasing cases in hospitals. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Immunomodulators Market Scope and Segmentation

Market Definition

Immunomodulators refer to the type of drugs that stimulate or suppress the immune system and alter the immune system that results in change in immune response. These drugs reduces the production of antibodies that react with foreign antigens showing immune responses. Immunosuppressants and Immunostimulants are characterized under the immunomodulators.

Global Immunomodulators Market Dynamics

Drivers

• Increase in the incidence of chronic diseases

The rise in incidence of chronic diseases such as asthma, allergic conditions, cancer, and multiple sclerosis, and availability of effective product pipeline of the companies involved in research and development of immunomodulators accelerate the market growth.

Increasing incidence of chronic diseases, including asthma, allergic conditions, cancer, and multiple sclerosis. Further, some of the factors contributing to the growth of the immunomodulator industry include the prevailing cases of organ transplantation, increasing adoption of an early immunomodulator therapy for the Crohn’s disease treatment, rising awareness about inflammatory bowel diseases, growing autoimmune diseases, and increasing development of drug resistance, which is resulting in the rise of immunomodulators usage.

• Rising number of geriatric population

Expanding geriatric population worldwide is predicted to favour the immunomodulators as this population is more prone to develop diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, endovascular diseases, infectious diseases, and dental disorders, which can foster the demand for the immunomodulators cases across the globe.

According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.

• Growing awareness as well as expansion of biotechnology and pharmaceutical sectors

Growing awareness levels amongst patients and physicians pertaining to the applications of monoclonal therapy in immunomodulation is presumed to be contributing toward market growth. The aforementioned factor is believed to boost the adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators market over the forecast period.

Moreover, the demand for immunomodulators is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the immunomodulators market in the above mentioned projected timeframe.

Opportunities

Furthermore, key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising demand for drugs has significantly heightened the need for new drug development via extensive clinical trials. Manufacturers are now focusing on remodelling their drug development processes in an attempt to cater to patient needs across the globe. High prevalence of cancer and chronic disorders such as HIV/AIDs, asthma, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, and other autoimmune diseases is considered one of the major causes of morbidity & mortality, particularly in patients with compromised immune systems.

Increasing advancement in technology and rising number of innovations along with rising product approvals which will further contribute by generating immense opportunities that will further expand the market's growth rate in the future.

Restraints/Challenges

On the other hand, high costs associated with immunomodulator products and stringent regulatory policies for approval of immunomodulators antibodies which will likely to act as market restraints factor for the growth of the immunomodulators in the above mentioned projected timeframe. Moreover, adverse effects of immunomodulator drugs including pain, inflammation, and epilepsy will projected to become the biggest and foremost challenge for the growth of the market in the forecast period of 2023-2030.

This immunomodulators market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunomodulators market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2022, Sun Pharma launched a dry eye treatment product in Canada named CEQUA, a calcineurin inhibitor immunomodulator that uses nano micellar (NCELL) technology to improve the bioavailability and physicochemical stability of cyclosporine to promote the ocular tissue penetration.
• In February 2021 Merck announced the acquisition of Pandion Therapeutics in which the acquisition adds the pipeline of candidates targeting a broad range of Autoimmune Diseases. Pandion has used its TALON technology to build a strong pipeline of candidates that aim to regulate the immune response and could be used to treat a variety of autoimmune conditions.

Global Immunomodulators Market Scope

The immunomodulators market is segmented on the basis of product, application, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Immunosuppressants
• Calcineurin Inhibitors
• Antibodies
• Antimetabolites
• Glucocorticoids
• Others
• Immunostimulants
• Vaccines
• Antibodies
• Others
• Others

Application

• Respiratory
• Human Immunodeficiency Virus (HIV)
• Oncology
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Immunomodulators Market Regional Analysis/Insights

The immunomodulators market is analysed and market size insights and trends are provided by country, product, application, end users and distribution channel.

The countries covered in the immunomodulators market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.  

North America dominates the immunomodulators market because of the presence of a large diseased population and surge the demand for immunomodulatory therapy within the region

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 owing to the presence of supportive government initiatives in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The immunomodulators market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for immunomodulators market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the immunomodulators market. The data is available for historic period 2010-2021.

Competitive Landscape and Immunomodulators market Share Analysis

The immunomodulators market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunomodulators market.

Some of the major players operating in the immunomodulators market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Services, Inc.(U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Amgen Inc.(U.S.)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc.(U.K.)
• Merck & Co., Inc.(U.S.)
• Squarex.(U.S.)
• BioRap Technologies LTD (Israel)
• Pfizer Inc.(U.S.)
• NPO Petrovax Pharm (Russia)
• ResoTher Pharma (Denmark)
• InDex Pharmaceuticals Holding AB (Sweden)
• Step-Pharma (France)
• Spring Bank Pharmaceuticals.(U.S.)
• Horizon Therapeutics plc (Ireland)
• iTeos (Germany)
• BioNTech SE (Germany)
• ZERIA Pharmaceutical Co., Ltd. (Japan)
• Atox Bio (Israel)